Please use this identifier to cite or link to this item:
https://swslhd.intersearch.com.au/swslhdjspui/handle/1/13035
Title: | WHAT ARE THE RISKS OF BIOLOGIC THERAPIES AND HOW DO YOU COMMUNICATE THEM TO PATIENTS? |
Author: | Connor, S. Wu, Y. C. |
Issue Date: | 2024 |
Journal: | Curbside Consultation in IBD: 49 Clinical Questions |
Abstract: | The range of biologic therapies currently available for treating inflammatory bowel disease (IBD) include anti-tumor necrosis factor (anti-TNF) agents, infliximab, adalimumab, certolizumab, and golimumab; one anti-adhesion molecule, vedolizumab; and one interleukin (IL) 12/IL-23 antagonist, ustekinumab. The foundation of selecting the optimal treatment for a patient with IBD rests in individualized assessment of a patient?s risk-to-benefit ratio. � 2022 by Taylor & Francis Group. |
ISSN: | 978-104013849-6 (ISBN); 978-163091650-3 (ISBN) |
Digital object identifier: | 10.1201/9781003523567-23 |
URI: | https://swslhd.intersearch.com.au/swslhdjspui/handle/1/13035 |
Appears in Collections: | Liverpool Hospital |
Files in This Item:
There are no files associated with this item.
Items in Prosentient are protected by copyright, with all rights reserved, unless otherwise indicated.